Trial Profile
Randomized, Double-blind, Single Subcutaneous Dose, Parallel Design Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses, in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Sanofi
- 08 Dec 2023 New trial record